Form 4: Tarsus Pharmaceuticals Director Acquires Stock Options and Restricted Stock Units

Katherine Goodrich, a director at Tarsus Pharmaceuticals, acquired 10,000 stock options and 6,700 restricted stock units on November 13, 2024.

Summary

• Katherine Goodrich, a director at Tarsus Pharmaceuticals, has reported the acquisition of 10,000 stock options and 6,700 restricted stock units.
• The stock options have an exercise price of $46.51 and will vest in three equal annual installments starting November 13, 2025.
• The restricted stock units (RSUs) will vest in three equal annual installments on December 15th of 2025, 2026, and 2027.
• Both the stock options and RSUs are subject to the director's continuous service with the company.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction, but the acquisition of equity by a director is generally viewed positively as it aligns their interests with shareholders. The sentiment is therefore moderately positive.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.
• The vesting schedules for both the options and RSUs incentivize long-term commitment from the director.

Industry Context

This is a standard SEC Form 4 filing, which is common for publicly traded companies when insiders such as directors acquire company stock or options. It is a routine part of corporate governance and transparency.

Comparison to Industry Standards

• The vesting schedules for the stock options and RSUs are typical for executive and director compensation packages in the biotechnology industry.
• Many companies, such as Amgen and Gilead, use similar vesting schedules to align the interests of management with long-term shareholder value.
• The exercise price of $46.51 for the stock options is a common practice, often set at or near the market price at the time of grant.

Stakeholder Impact

• The acquisition of equity by a director can be viewed positively by shareholders as it aligns management's interests with the company's long-term success.
• The vesting schedules ensure the director's continued commitment to the company.

Key Dates

Keywords

stock options, restricted stock units, director, insider trading, Tarsus Pharmaceuticals, equity compensation, vesting